Nanotechnology Now - News Story: As the drug market moves to injectables, biotech majors strive to develop targeted-injection drugs for the treatment of a host of disorders

Home > News > As the drug market moves to injectables, biotech majors strive to develop targeted-injection drugs for the treatment of a host of disorders

April 29th, 2007

As the drug market moves to injectables, biotech majors strive to develop targeted-injection drugs for the treatment of a host of disorders

Abstract:
Indian biotech majors, however, seem steady on their path. Dabur Pharma, for instance, achieved a breakthrough with its Nanoxel—a drug delivery system for the widely used anti-cancer drug Paclitaxel. This nanoscale drug delivery system is India's first indigenously developed nanotechnology-based chemotherapy agent, and also the first outside of the US. Positioned as a safer therapy for advanced breast, non-small-cell lung, and ovarian cancers, it enables therapy to take a preferential course to the cancerous cells and directly interact with the tumour-causing agents thereby throwing open a larger window for anti-tumour activity. It also ensures that the patient receives the full measure of therapy while limiting the adverse side effects and toxicity affected by the drug. This would be a great advantage because the biggest challenge faced in cancer therapy is the incidence of severe side effects that the cancer patient has to encounter while undergoing chemotherapy.

Source:
financialexpress.com

Bookmark: